UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $325,000 in GeneDx Holdings Corp. (NASDAQ:WGS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,647 shares of the company's stock, valued at approximately $325,000.

A number of other large investors have also added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new position in shares of GeneDx in the 2nd quarter valued at approximately $34,000. nVerses Capital LLC bought a new position in GeneDx in the second quarter valued at approximately $50,000. CWM LLC acquired a new position in GeneDx during the third quarter valued at approximately $89,000. SG Americas Securities LLC bought a new stake in GeneDx during the third quarter worth $198,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of GeneDx in the 3rd quarter valued at $287,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Wells Fargo & Company boosted their target price on GeneDx from $34.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 30th. Finally, Craig Hallum raised their price target on shares of GeneDx from $70.00 to $95.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $59.33.

GeneDx Trading Up 2.8 %

GeneDx stock traded up $2.10 during trading hours on Friday, hitting $77.40. The stock had a trading volume of 693,093 shares, compared to its average volume of 459,327. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of -24.89 and a beta of 2.03. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The business's 50 day simple moving average is $72.46 and its 200-day simple moving average is $47.51. GeneDx Holdings Corp. has a one year low of $2.47 and a one year high of $89.11.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The business had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. During the same period last year, the company earned ($0.82) EPS. The firm's revenue was up 44.3% compared to the same quarter last year. On average, equities analysts predict that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Insider Transactions at GeneDx

In other news, CEO Katherine Stueland sold 2,154 shares of the business's stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $66.60, for a total value of $143,456.40. Following the transaction, the chief executive officer now owns 105,426 shares in the company, valued at approximately $7,021,371.60. The trade was a 2.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Feeley sold 3,728 shares of the company's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $76.75, for a total transaction of $286,124.00. Following the completion of the sale, the chief financial officer now directly owns 28,200 shares in the company, valued at approximately $2,164,350. This represents a 11.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,123,603 shares of company stock worth $83,300,382. Company insiders own 27.30% of the company's stock.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.